PolarisAIPharma established in 1996 is an enterprise
specialized for producing raw pharmaceutical ingredients.

Focusing on generic medicine, we’ve produced and supplied approximately 40 kinds of raw pharmaceutical
ingredients such as medicine for asthma, gastric ulcer and dependence on alcohol etc. at home and abroad.

Generic medicine means the medicine with identical quality which is made of technologies and raw materials
which are open to the public after the patent period of original medicine expires.

Among them, the first product is called as ‘First Generic’, and preoccupancy of the market is more
important than anything else.

PolarisAIPharma owns significant numbers of products based on our own technical skills,
and aside from it, we’re leading the development of a variety of raw pharmaceutical ingredients.

The new factory with one basement floor and 4 floors above the ground which is equipped with a production hall and a utility hall, R&D center etc. was completed at Hwaseong, Gyeonggi-do in Apr 2008, which is the equivalent level of c-GMP (the standard for facilities producing medicine in the U.S.).

In case of a production hall, it has the cutting-edge facility that is the completely enclosed system from infusion of raw materials to production, which became an opportunity to get rid of concerns of the people around us and to prepare for a foundation of the 2nd jump with the investment exceeding the sales at the juncture of investment, and we’re reborn as a company having an ability of production of the global level by extending the Production Hall B in 2011.

PolarisAIPharma has been actively conducting marketing activities for the purpose of overseas
market since the early years of its establishment, and achieved an award of $30-Million Export
Tower in 2012 from the Korea International Trade Association (KITA).

The export proportion of the sales accounts for over 60% on average, and among them, the export proportion to
Japan requiring very strict quality control and verification on technical skills accounts for over 70%. A such, we’re
established with technical skills and reliability.

In the near future, we’re planning to expand advancement to Europe and the U.S. and to enter more overseas
market actively especially to South America, Southeast Asia and Middle East etc. Besides, PolarisAIPharma
is actively devoting at new projects by selecting/supporting/investing domestic bio/pharmaceutical venture
enterprises so that they can develop medicine able to be recognized in the world.

" We’ll make sure to make our best efforts to grow up as a global pharmaceutical company based on active pioneering overseas markets and investment on innovative infrastructure"